Santhera Pharmaceuticals Bonds, 5% 17feb2022, CHF (Conv.) (FIGI BBG00FZ8R6T6, CH0353955195, WKN A19DGL)
Domestic bonds, Convertible, Senior Unsecured
Domestic bonds, Convertible, Senior Unsecured
Everything you need for fixed income research and monitoring.
Explore the most comprehensive database
1 000 000
bonds
100 000
stocks
175 910
ETF & Funds
100 000
indices
Track your portfolio in the most efficient way
full data on over 1 000 000 bonds, 100 000 stocks, 100 000 indices, 17 000 ETF and 150 000 Mutual Funds; powerful bond screener; over 350 pricing sources among stock exchanges & OTC market; ratings & financial reports; user-friendly interface; available anywhere via Website, Excel Add-in and Mobile app.
Register|
Santhera Pharmaceuticals is a Swiss drug discovery and development company. It is focused on the development of treatments for neuromuscular and neuro-ophthalmological diseases that currently lack treatment options. The company was founded in 2004 through the ...
Santhera Pharmaceuticals is a Swiss drug discovery and development company. It is focused on the development of treatments for neuromuscular and neuro-ophthalmological diseases that currently lack treatment options. The company was founded in 2004 through the merger of two start-up biotech companies, MyoContract and Graffinity Pharmaceuticals. Santhera’s headquarters are located in Liestal, Switzerland, with subsidiaries in Germany, UK, Italy, Netherlands, Liechtenstein, US and Canada.
|
|
|
|
|
|
|
|
|
Explore the most comprehensive database
1 000 000
bonds
100 000
stocks
175 910
ETF & Funds
100 000
indices
Track your portfolio in the most efficient way
full data on over 1 000 000 bonds, 100 000 stocks, 100 000 indices, 17 000 ETF and 150 000 Mutual Funds; powerful bond screener; over 350 pricing sources among stock exchanges & OTC market; ratings & financial reports; user-friendly interface; available anywhere via Website, Excel Add-in and Mobile app.
Register